Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324885 | 0.84 | MEN1 (0.41) | HSD17B10MEN1ALDH1A1KMT2AROCK2 | |
| SCHEMBL20329137 | 0.76 | PIK3CD (0.40) | HSD17B10MEN1ALDH1A1KMT2AROCK2 | |
| SCHEMBL7904346 | 0.76 | CYP1A2 (0.52) | HSD17B10ALDH1A1CHRM1HPGD | |
| SCHEMBL17708306 | 0.76 | CYP1A2 (0.52) | HSD17B10ALDH1A1CHRM1HPGD | |
| SCHEMBL17708305 | 0.76 | CYP1A2 (0.52) | HSD17B10ALDH1A1CHRM1HPGD | |
| SCHEMBL1417346 | 0.75 | MMP1 (0.44) | MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL3288873 | 0.75 | MMP1 (0.44) | MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL3298525 | 0.75 | MMP1 (0.44) | MEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL20970532 | 0.74 | MEN1 (0.35) | HSD17B10MEN1ALDH1A1KMT2AROCK2 | |
| SCHEMBL22025301 | 0.74 | MEN1 (0.35) | HSD17B10MEN1ALDH1A1KMT2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | HSD17B10 3956/4885MEN1 1084/4885ALDH1A1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.